Trials / Completed
CompletedNCT00111683
MK0457 in Patients With Leukemia (0457-003)
A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.
Conditions
- Chronic Myelogenous Leukemia in Blast Crisis
- Lymphocytic Leukemia, B Cell, Acute
- Myelodysplastic Syndromes
- Myelogenous Leukemia, Chronic
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0457 |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2005-05-25
- Last updated
- 2015-08-25
Source: ClinicalTrials.gov record NCT00111683. Inclusion in this directory is not an endorsement.